Regencell Bioscience Holdings Limited (NASDAQ:RGC – Get Free Report) shares saw unusually-high trading volume on Wednesday. Approximately 234,856 shares traded hands during mid-day trading, a decline of 17% from the previous session’s volume of 283,209 shares. The stock last traded at $8.43 and had previously closed at $8.19.
Wall Street Analysts Forecast Growth
Several research firms have recently issued reports on RGC. Weiss Ratings reissued a “sell (e+)” rating on shares of Regencell Bioscience in a research note on Monday, September 21st. Wall Street Zen lowered Regencell Bioscience from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.
Regencell Bioscience Price Performance
The stock has a 50-day moving average price of $6.17 and a 200 day moving average price of $14.20.
Regencell Bioscience (NASDAQ:RGC – Get Free Report) last released its quarterly earnings results on Wednesday, October 7th. The company reported ($0.01) earnings per share (EPS) for the quarter.
Institutional Trading of Regencell Bioscience
Several institutional investors have recently modified their holdings of the stock. Bank of America Corp DE raised its position in shares of Regencell Bioscience by 59,113.8% during the 1st quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock worth $437,000 after purchasing an additional 17,143 shares during the last quarter. Amundi acquired a new stake in Regencell Bioscience in the 1st quarter worth about $219,000. Finally, Seven Fleet Capital Management LP acquired a new stake in Regencell Bioscience in the 4th quarter worth about $92,000. Institutional investors and hedge funds own 0.13% of the company’s stock.
About Regencell Bioscience
Regencell Bioscience Holdings Limited is a clinical-stage biotechnology company focused on developing traditional Chinese medicine (TCM) treatments for neurocognitive disorders and degenerative conditions. Its research has centered primarily on conditions such as dementia and attention-deficit/hyperactivity disorder (ADHD), with the goal of developing herbal formulations that may address underlying symptoms and disease-related challenges.
The company’s product development programs include proprietary TCM formulations intended for neurological and cognitive conditions.
Further Reading
- Five stocks we like better than Regencell Bioscience
- ASML Can’t Keep Up With AI Demand—Why That’s a Good Thing
- Enovix’s 100,000-Battery Drone Order Sets Up a Test of Its Production Plans
- AMD’s Support Could Help Fermi Stock Overcome Its Biggest Hurdle
- Beyond the GPU: Credo Paves the Next AI Data Superhighway
Receive News & Ratings for Regencell Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regencell Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
